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ABSTRACT    
  The TREAT Consortium has carried out clinical studies on alcoholic hepatitis (AH) for 
over four years.   We encountered problems with participant recruitment, retention, and 
eligibility for specific protocols. To improve our ability to carry out such trials, we reviewed 
recruitment screening logs, end of study logs, and surveyed study coordinators to learn the 
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reasons for missing patients, why patients declined enrollment, and the number of patients 
eligible for treatment trials.  Associations of the recruited subjects’ demographics with their 
adherence to follow-up appointments were examined.  387 patients (AH and heavy drinking 
controls) were enrolled in the observational study and 55 AH patients were recruited into 
treatment trials.  About half of patients identified with AH could not be recruited; no specific 
reason could be determined for about two thirds of these.  Among the patients who gave a 
reason for not participating, the most common reasons were: feeling too sick to participate, 
desire to concentrate on abstinence, and lack of interest in research.  Approximately a 
quarter of the AH patients met eligibility criteria for treatment trials for moderate or severe 
AH and we were able to recruit half to two thirds of those eligible.  Approximately 35% of 
participants in the observational study returned for both 6 and 12 month follow-up visits. We 
did not identify biopsychosocial or demographic correlates of retention in the study. This 
analysis revealed that attempts at recruitment into trials for AH miss some subjects because 
of structural issues surrounding their hospital admission, and encounter a high rate of patient 
refusal to participate. Nonetheless, more than half of the patients who met the eligibility 
criteria for moderate or severe AH were entered into clinical trials.  Retention rates for the 
observational study are relatively low. These findings need to be accounted for in clinical trial 
design and power analysis.  
 
Key words: alcoholic hepatitis, recruitment, retention, clinical trial, MELD score 
 
 Alcoholic hepatitis (AH) is a serious public health problem with a high mortality rate. 
When severe, as judged by the MELD over 19 or Maddrey discriminant function over 32, 
mortality approaches 50% within the first 30-90 days; those surviving the acute phase still 
carry a high risk of dying in the ensuing year (Mathurin and Bataller, 2015).  Analysis of 
hospital and insurance administrative data suggests that the incidence of (AH) is rising 
(Jinjuvadia and Liangpunsakul, 2015). The only widely used therapy, corticosteroids, is at 
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best modestly effective and has significant contra-indications and side effects.  No new 
therapies are near introduction into clinical practice.  Animal models for AH do not fully 
recapitulate the human disease; thus, clinical research is vital to this field for the 
development of new treatment modalities and non-invasive diagnostic techniques. 
 In response to the dearth of treatment options for these patients, the National 
Institute on Alcohol Abuse and Alcoholism (NIAAA) has funded four consortia to accelerate 
AH research. The Translational Research and Evolving Alcoholic hepatitis Treatment 
(TREAT) consortium launched an observational study (TREAT001) in 2012 for patients with 
(AH), defined as recent onset of jaundice (bilirubin >2 mg/dL), aspartate transaminase (AST) 
> 50 U/L, and a history of heavy alcohol consumption (> 40 grams per day on average in 
women and 60 grams per day in men) for a minimum of 6 months and within the 6 weeks 
prior to study enrollment.  The patients underwent clinical evaluation and appropriate 
laboratory testing to exclude confounding issues (negative markers for autoimmune liver 
disease and metabolic liver disease; absence of sepsis, shock, cocaine use, or recent drug 
use with drug-induced liver injury (DILI) potential within 30 days).  Co-existing HCV or HBV 
infection did not mandate a liver biopsy if other features were consistent with AH.  With 
confounding factors, or atypical laboratory tests (AST <50 or >400 IU/mL, AST/ALT ratio 
<1.5, ANA >1:160 or SMA > 1:80), a liver biopsy (if clinically feasible and the subject has no 
contra-indications) was required.    
TREAT001 also includes heavily drinking controls who are individuals with no history 
of alcoholic liver disease, AST and alanine aminotransferase (ALT) ≤ 50 U/L, and normal 
total bilirubin. This study required completion of several survey instruments, a physical 
examination with anthropomorphic measurements, and collection of biosamples (blood, 
urine, stool) for archiving. Participants are scheduled to return for follow-up visits at 6 and 12 
months. Study participants receive a payment of up to $255 dollars for completing all study 
visits and vouchers to cover parking expenses when applicable. TREAT also conducts 
phase 1 and 2 clinical trials for patients with moderate (MELD < 20) and severe AH (MELD 
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>19 but <29). Clinical trial participants are randomized to placebo or active drug and require 
more frequent follow-up visits during the treatment phase. All treatment trial participants are 
concurrently enrolled in the observational study.   
 Recruitment and retention of subjects in clinical trials related to alcohol abuse is 
difficult. These challenges have been discussed with regard to two very large randomized, 
controlled trials carried out with NIAAA support over the last several decades, Project 
MATCH (Zweben et al, 1994) and the COMBINE Study (Zweben et al., 2005). These studies 
examined various alcohol abuse treatments and required frequent contact as part of their 
patients’ therapy. To extend these analyses and explore possible additional issues related to 
recruitment and retention of patients with liver disease in addition to alcohol use disorders, 
we reviewed four years of experience in TREAT.  We examined reasons patients gave for 
not participating in the studies, and factors correlating with failure to complete 6 and 12 
month follow-up visits.  To improve patient recruitment for future clinical trials, we analyzed 
the TREAT001 patients to see what proportion would be eligible for the current trials and our 
success in recruiting them. Strategies to improve enrollment and retention are suggested, 
based on the experiences of the study coordinators and investigators.  
 
RECRUITMENT TO THE OBSERVATIONAL STUDY     
We retrospectively analyzed our experiences recruiting patients over four years. 
Recruitment sites included Indiana University, Indianapolis, IN; Mayo Clinic, Rochester MN; 
and Virginia Commonwealth University, Richmond, VA.  We did not initially develop a formal 
process for tracking possible recruits; we therefore reviewed recruitment screening logs and 
end of study logs, and surveyed study coordinators to estimate the numbers of patients with 
AH we encountered and to learn the reasons for missing potentially eligible patients.  
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We estimated the numbers of patients with AH encountered during the first 4 years of 
the study (Table1).  There were structural issues in the health systems reported by the 
coordinators that impacted the study teams’ ability to recruit patients. Most patients were first 
seen by general medical teams (hospitalists) less familiar with AH (and perhaps with the 
common overlap between AH and cirrhosis), and who may start therapy before the patients 
can be seen by consulting hepatologists involved in treatment trials. Additionally, as is the 
case with many clinical trials, it was difficult to identify AH patients immediately following 
hospital admission without manual medical record screening.  Relying on reminders to the 
medical teams to refer AH patients for to the study team did not suffice. There were also 
instances where patients were discharged before study coordinators could speak with them 
due to the delayed referral. In general, Spanish speaking patients were not enrolled due of 
the difficulties inherent in working though interpreters and a lack of validated Spanish 
language study documents and diagnostic instruments. 
We then turned to self-reported reasons for declining to participate in the studies; the 
patient responses were recorded in recruitment logs and are compiled in Table 1. The study 
coordinators were also surveyed to capture their recollection of reasons why patients 
declined participation and the results were similar (Table 2). It is striking that a) only about 
half of patients identified as likely having AH could be enrolled in a study and b) a reason for 
declining to participate was available for only about one third, but we did not systematically 
collect this information or followup with further questioning.  In the future, it may be beneficial 
to ask patients to elaborate on why they are not interested to make sure they understand the 
information they are given about AH and the study. The other reasons fell into several broad 
categories that also overlapped with reasons participants failed to complete the study. 
Common reasons cited by study coordinators for participants being lost to follow-up or 
withdrawing from the study were inability to contact participants, relocation or lack of 
transportation, and lack of interest in research. 
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One category of responses reflected a poor understanding of AH and research by 
patients. Noted issues included the observation by coordinators that patients did not 
understand the severity of their disease, felt too sick to participate, and did not see any 
personal benefit from participation. A second category revolved around social issues: 
homelessness, lack of transportation, anticipated moving to another locale, and study 
coordinators noted that financial issues also played an important role. Third, it was 
interesting that a number of patients did not accept the diagnosis of AH because they did not 
feel they drank excessively (or at all!). There were overtones of distrust for researchers or 
research studies, including a concern about the privacy of the records. Privacy concerns 
could reflect the stigma of alcohol use disorders or concern about the impact of this 
diagnosis on family or employers. One interesting observation that touches on the consent 
process was the comment that patients may feel that their show of altruism (by participating 
in medical research) might be beneficial to them in pending legal proceedings: such patients 
might need to be considered vulnerable in the sense that prisoners are vulnerable.  
ELIGIBILITY FOR CLINICAL TRIALS 
The clinical characteristics of the patients recruited into the TREAT001 study have 
been previously reported (Liangpunsakul et al., 2016).  The patients were mainly middle-
aged white men who were very heavy drinkers. Over half had severe AH (MELD >19). 
Twelve month mortality was under 2% for control subjects, and about 25% for AH cases. All 
patients in the clinical trials were first enrolled in TREAT001, so in order to assess the 
feasibility of enrolling subjects into future clinical trials, the entry characteristics and 
laboratory values of AH patients recruited through 6/27/2016 into TREAT001 were compared 
to exclusion and inclusion criteria for TREAT002, TREAT003, and TREAT008, three ongoing 
clinical trials for assessing efficacy of therapeutic agents for AH. The flow of patients into 
these studies, and their retention, is summarized in Figure 1.   
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 TREAT002 sought to enroll patients with moderately severe AH (MELD between 11 
and 19) for treatment with an FXR agonist. TREAT003 enrolled patients with severe AH 
(MELD >19) for treatment with oral immunoglobulin against lipopolysaccharide in addition to 
steroids. TREAT008 studies the effect of IL-22 in patients with moderate or severe AH.  
Each study had exclusion criteria related to renal function, treatment with other agents prior 
to enrollment, and other co-morbidities. There were 218 AH cases in the TREAT001 study 
with at least some data collected at their baseline visit.  Of this entire group, 58 (27%) met 
eligibility criteria for TREAT 002 and 41 (19%) were eligible for TREAT003 at baseline.  
TREAT001 began about 2 years before the treatment trials, and there were slightly over 100 
AH patients enrolled while the treatment trials were recruiting patients.  After accrual for 
TREAT002 began, 24 of 102 (23.5%) were eligible and 13 (54.2%) of these were enrolled. 
Two other subjects eligible for TREAT002 were enrolled in TREAT008.  After accrual for 
TREAT003 began, 27 of 109 (24.8%) of TREAT001 individuals were eligible for entry, and 
18 (67%) of these individuals were successfully enrolled. The most common cause of 
ineligibility for TREAT002 was a high MELD score. For TREAT003 candidates with severe 
AH, ineligibility was most commonly due to the treating physicians not intending to treat with 
steroids, creatinine elevated above 1.5 mg/dl, and co-existing viral hepatitis. The TREAT008 
study was activated most recently and therefore a smaller number of AH patients were 
encountered. Ten of 21 (67.1%) were eligible for entry into TREAT008 and we enrolled 3 
(30%) of them; 3 individuals who were eligible for TREAT008 were enrolled in either 
TREAT002 or TREAT003. The numbers of patient eligible for the clinical trials at the time of 
recruitment into TREAT001 is lower than the numbers actually recruited (Figure 1), because 
the clinical status of some patients changed after their initial enrollment; in particular, 18 
patients who were not eligible for TREAT003 at baseline suffered worsening of their AH 
severity scores and became eligible.  
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RETENTION OF PATIENTS IN THE STUDIES 
We compared baseline demographic and biopsychosocial information between the 
patients in the TREAT001 cohort who returned for follow-up at 12 months vs those who did 
not return to determine patient and social factors that reduced the likelihood of the 
participant completing follow-up visits. We also reviewed research coordinator logs to learn 
of other factors which interfered with retention. For continuous variables, a t-test was 
employed to test for a difference in means by AH status, while for categorical variables, a 
Chi-square test was used.   
From the entire TREAT cohort (AH cases and heavy drinking controls), a total of 310 
participants had been followed long enough to either miss their 6 month visit or successfully 
complete it.  Of those participants, 164 or 52.9% (91 (58%) of cases and 73 (48%) of 
controls) returned for the 6 month follow-up visit (which we prospectively defined as 
returning between 3 and 9 months after recruitment). A total of 263 participants had been 
followed long enough to either miss their 12 month visit or successfully complete it.  Of these 
participants, 128 or 48.7% (63 (49.6%) of cases and 65 (47.8%) of controls) returned for a 
12 month follow-up visit (which we prospectively defined as returning between 9 and 15 
months after recruitment), although 32 (19 cases, 13 controls) of these individuals failed to 
return for the 6 month visit. Only 96 or 36.5% (44 (34.6%) of cases and 52 (38.2%) of 
controls) returned for both the 6 and 12 month visits. 
We examined demographic and other characteristics of the study participants for 
correlations with failure to return for follow-up visits. There was no evidence of an effect for 
sex, age, or race of the subject on the likelihood of dropping out by 12 months. Similarly, two 
social factors we examined were not found to correlate with drop-out: marital status (married, 
divorced or widowed, or single/never married) or level of educational achievement (less than 
year 10, completed high school, trade school/some college, standard college/university, and 
completed graduate/professional). Several additional biopsychosocial factors were 
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examined: self-rating of health using the first question of the SF36 questionnaire, treatment 
arm (cases vs controls), MELD score, and regular use of marijuana.  There was no statistical 
evidence that these factors were associated with the participant returning for 12 month visit.  
RECOMMENDATIONS TO IMPROVE RECRUITMENT AND RETENTION IN 
TRAILS FOR ALCOHOLIC HEPATITIS.     
 Alcoholic hepatitis and heavy drinking controls were difficult to identify early in their 
medical trajectory, to recruit, and to retain for follow-up visits.  Fewer than half of the patients 
identified as having probable AH were enrolled in any study, including a purely observational 
study. The proportion eligible for trials was rather low (20-25% based on TREAT002 and 003 
criteria) and our ability to recruit them was fair at best (50-67%).  Only about a third of those 
enrolled in the observational study completed both 6 and 12 months visits. It was striking 
that there was no difference in retention rates between the heavy drinking controls and the 
patients with AH, indicating that the underlying problem with retention is related to the 
alcohol use disorder, not the liver disease.  
These challenges will need to be overcome to conduct larger phase 3 studies.  We 
perceive three different types of problems to be addressed: identification of the patients, 
recruitment into trials, and retention in the studies. These issues can be addressed with 
revised study design, improved communication by the study teams during the enrollment 
and throughout the study, and development of educational materials for patients and 
families. 
The structural issues in the health systems which interfere with identifying patients 
may be the easiest to address. Identification of AH patients admitted to the hospital can be 
facilitated using IRB-approved automated screening of patients’ admission laboratory data 
by the electronic health record. Once possible participants are identified, research teams can 
contact the patient’s physician for permission to engage the patient. This approach facilitates 
finding patients admitted over the weekend/holidays or leaving the hospital after a short stay 
(in particular those with moderately severe AH).  It appears that there is insufficient 
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appreciation by hospital medicine teams that AH commonly coexists with alcoholic cirrhosis, 
leading to misclassification as simply decompensated cirrhosis, rather than AH.   The study 
coordinators noted that the involvement of consulting physicians leading the trial was very 
important in recruitment, which could reflect the need for greater patient education about this 
little known liver disease.  
The recruitment challenges seem to be related to individual patient characteristics, 
but with specific reasons for declining to participate available for only one third of the 
patients, we suggest future studies systematically explore these reasons to improve our 
ability to recruit. Improved communication between study teams and potential participants 
may overcome this. Knowledge of the serious nature of AH (40-50% 90 day mortality) by 
patients and families may generate interest in clinical research participation to improve their 
outcome.  Some patients declined to participate because they did not feel the study would 
provide any benefit or they wanted to prioritize sobriety and recovery. To address those 
concerns, incorporation of medication-assisted treatment, possibly with baclofen (Addolorato 
et al., 2007), could be considered in future trials.  A double blind study of the effectiveness of 
baclofen in patients with alcoholic liver disease is underway in Australia (Morley et al., 2013); 
it will be important to clarify the effect of AH on the pharmaco-dynamics and -kinetics of 
baclofen.  The added emphasis on treatment of alcoholism per se could rightly be promoted 
as a benefit of participation in the trial, and reinforced as one of the reasons follow-up is 
essential.  Trial sponsors would need to support this treatment phase of the trial, if the 
participant’s insurance plan does not.   
Other barriers to enrollment include ineligibility because of incarceration and 
cognitive impairment from encephalopathy.  Language barriers with Spanish-speaking 
patients also hinder recruitment.  Hispanic patients may have an increased risk of AH ( the 
PNLPA3 variant, common in Hispanics, which confers risk of non-alcoholic steatohepatitis 
(Romeo et al., 2008) and alcoholic cirrhosis (Stickel et al., 2011; Buch et al. 2015) also 
increases risk for AH (Liangpunsakul, et al, 2016). Future studies could incorporate validated 
and IRB-approved Spanish translations of consent documents, surveys, and other data 
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collection instruments (e.g., the Time Line Follow-Back survey, and instruments used to 
detect concomitant mental health disorders).    
The social issues of patients with alcoholism are more difficult to address. Lack of 
transportation, parking costs, and other financial issues could be dealt with through gift cards 
given at each visit.  Involvement of family and friends in the review of drinking history, and 
counseling of the patient, might overcome the denial of hazardous drinking.  Regular contact 
with participants between study visits can help keep study coordinators aware of changing 
contact information and relocation plans. To address distrust of research, study teams must 
explain the human subjects’ protection and privacy regulations. A certificate of confidentiality 
(COC) might reassure the patients that the diagnosis of an alcohol use disorder could not be 
used against them at work or in legal situations.  However, there may by limitations that 
would prevent investigators from obtaining a COC. The TREAT consortium was unable to 
obtain a COC due to federally mandated documentation required of investigators that 
conflicted with the guidelines of the COC. 
A number of patients were excluded from trials because of concomitant viral hepatitis 
or other medical illness (HIV infection, advanced heart failure, chronic obstructive pulmonary 
disease, renal failure, active substance abuse). These issues are difficult to avoid because 
such exclusions may be required by sponsors for specific trials.  Even those eligible for a 
clinical trial commonly declined enrollment.  The barriers to trial participation mirrored those 
affecting enrollment into the observational study. A more significant challenge is the 
increased time commitment required of clinical trial participants. The additional study visits 
required for participation can be too burdensome for working individuals and those with 
transportation challenges. Offering study visits outside of standard working hours and 
providing additional assistance with transportation may lessen the participant burden of 
participating in clinical trials. 
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Study coordinators also noted cases where eligible patients were unable to participate due 
to homelessness and the resulting inability to store investigational products in a secure and 
temperature-stable location.  
 Lastly, retention in the TREAT001 study was rather poor, with about half of 
participants returning at 6 months and only 35% completing both 6 and 12 month visits.  We 
were surprised that none of the demographic factors we assessed were associated with 
study retention. The end of study logs revealed that the patients move often, change 
telephone numbers, and have less reliable contact information. Family support may be 
lacking because of the destructive effect of alcohol dependence on relationships. 
Participants are, of course, at risk of relapse to heavy drinking during the follow-up period. 
An interesting observation was that many participants missed the 6 month visit but returned 
at 12 months. This suggests that visits are not simply missed because individuals decided 
against further participation in the study. With improved and more frequent communication 
between study coordinators and participants, it may be possible to improve followup 
attendance.  Future efforts may explore how to manage the participants remotely for some of 
the follow-up visits.  A long distance approach would address the inconvenience of return 
visits.   
 These issues have been analyzed in detail by the leaders of Project MATCH and the 
COMBINE Study.  Project MATCH excluded individuals with ongoing use of other 
substances, low social stability (i.e., being unable to provide a “locator” who would be able to 
help investigators follow-up), and dual diagnoses of other mental health problems (Zweben 
et al., 1994). The COMBINE study tested pharmacological agents to reduce drinking 
reported their experience in more detail (Zweben et al., 2005). They attempted to risk stratify 
the potential enrollees, which included assessment of the patients’ insight into their drinking, 
possible negative attitudes about pharmacotherapy, interest in reducing drinking (four days 
of abstinence were required before enrollment), and willingness to participate in a placebo-
controlled study. Red flags during recruitment included the patient complaining about 
demands of the study, failing to return calls, or being unable to schedule appointments. 
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Much attention was devoted to maintaining high retention, including reducing the time 
demands of follow-up visits, asking for explanations for why participants missed follow-up 
visits, and addressing the potential embarrassment of patients who had relapsed into heavy 
drinking.   
In conclusion, we offer the strategies described in Table 3 as means to improve the 
ability to recruit and retain patients with AH and heavy drinking controls for future studies. 
The experience of the TREAT consortium provides data that will be useful in power analysis 
and the design of these much needed trials.  
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Legend to Figure 1.  
CONSORT diagram of the recruitment and retention of patients with alcoholic 
hepatitis (cases) and heavy drinking controls (controls). The windows for completing a 
followup visit were returning between 3 and 9 months after enrollment for the 6 month time 
point, and returning between 9 and 15 months for the 12 month time point.  
 
 
Table 1. Reasons for declining to enroll in the TREAT studies 
 
Total potential alcoholic hepatitis patients  431 
Total alcoholic hepatitis patients enrolled 218 
Total unable to recruit 213 
Reason for declining Number of 
individuals (% of 
total declining) 
Reason not specified 136 (63%) 
Too sick/not feeling well/poor prognosis 20 (9%) 
Patient unable to consent 13 (6%) 
Not interested in research 11 (5%) 
Does not accept alcoholic hepatitis diagnosis /denies 
drinking/alcoholism 
8 (4%) 
Homeless 6 (3%) 
Wants to focus on sobriety and/or getting better/recovery 6 (3%) 
Transportation concerns/unable to complete follow up visits 5 (2%) 
Soon to be discharged from the hospital/Going home 5 (2%) 
Concerns from patient family or spouse 5 (2%) 
Too busy/time concerns/ “too much going on” 2 (1%) 
Going to rehab 3 (1%) 
No benefit from participating 2 (1%) 
Moving soon 1 (1%) 
Currently in another research study 2 (1%) 
 
 
This information was gathered from the study coordinators’ recruitment logs. There 
was variability in what constituted a “potential alcoholic hepatitis patient”, as some 
hospitalized patients were discharged before a careful chart review could be performed.  
Thus the total potential patients and total unable to recruit are approximations. Some 
patients gave more than one reason for not wanting to participate.  
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Table 2.  Results of survey of research coordinators 
What were the reasons given by 
patients for not participating in the 
observational study (TREAT001) 
and for treatment trials? 
This will not benefit me. Not interested. I wasn’t drinking 
that much. I am going to quit. I quit drinking already. 
Sometimes family members advise against enrolling. No 
transportation. Denial of active drinking. Sounds like too 
much work. Wants nothing to do with research. 
Participated in research in the past and doesn’t want to 
do again. Want to focus on getting better. Going home 
to drink. 
How were patients identified for 
possible enrollment?   
Hepatology consults, messages from admitting fellows, 
referring clinics, emergency department, hepatology 
inpatient service, hospital admission logs. 
Did you encounter difficulties 
connecting with patients referred 
for possible enrollment?    
Failing follow-up appointments. 
What questions did families and pa
frequently raise about enrolling in o
studies? 
What is the benefit for me?  How much travel time will 
this take? How will this affect my care? Will I be able to 
maintain privacy of my records?  
Do you think that the patients and 
families understood the serious 
nature of alcoholic hepatitis? 
No (reported from all sites). 
Did the desire of the patient or 
family for alcoholism treatment 
overshadow their willingness to 
participate in the trial (would 
incorporating alcoholism 
treatment more explicitly in the 
alcoholic hepatitis trials improve 
recruitment?) 
Probably. Maybe.  No, treatment wouldn’t increase 
enrollment.  
What factors seemed to increase 
the patients’ willingness to 
participate? 
Monetary compensation (including for transportation or 
cell phones). Extra medical care. Patients facing legal 
issues may wish to enroll as a show of good intentions. 
Were there actions of the primary 
team caring for the patients that 
resulted in them being ineligible 
or un-recruitable for studies you 
were recruiting for?  
 Starting various treatments prior to consultation 
(steroids, antibiotics).  
What would make your job as a 
research coordinator easier, more 
efficient, and more rewarding?  
Less searching for patients to enroll. More physician 
involvement with recruiting.  
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Table 3. Recommended strategies for recruitment and retention of AH patients in 
clinical trials 
 
To improve recruitment 
 
 
To improve retention 
 
a. Develop mechanisms at the 
recruiting hospitals and other sites 
to use the electronic medical 
record to systematically identify 
patients likely to have alcoholic 
hepatitis and to encourage 
immediate contact with patients 
and their providers.  
 
b. Educate primary care physicians, 
advanced practice providers, and 
hospitalists about the diagnosis, 
natural history and treatments for 
alcoholic hepatitis, and the 
importance of additional clinical 
trials.  
 
c. Create informational brochures, in 
English and Spanish, for patients 
and families describing the natural 
history and mortality of AH, the 
rationale for blinded, randomized 
studies, and the standards of 
protection of research subjects.  
 
d. Include in the study manuals 
materials that can be used for 
recruitment of Spanish-speaking 
patients, including brochures, 
handouts, informed consent 
statements, and survey 
instruments. 
 
e. Explain trial options for patients 
and the need to delay institution of 
treatment (e.g., steroids) that 
could affect eligibility. 
 
f. Include certificates of 
confidentiality in the consent 
process 
a. Formalize the identification of a 
“locator” for each patient.  
 
b. Develop eligibility criteria which 
address the likelihood that the 
patient will adhere to the protocol 
and remain in the trial. 
 
c. Include alcoholism treatment as 
part of the protocol as a standard 
of care.  
 
d. Consider the “participation 
burden”, i.e., complexity of 
interviews and measures, in 
particular for patients recruited in 
observational studies, and permit 
flexibility in follow-up demands to 
retain the patients. 
 
e. Emphasize to enrollees the value 
of maintaining contact throughout 
the study regardless of their ability 
to abstain.  
 
f. Establish protocols in the study 
manuals for close tracking of and 
specific responding to failure of 
follow-up. 
 
g. Increase financial support for 
participation, with increased 
incentive for completing all parts 
of the study over time.  
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